Neprilisin and angiotensin receptor inhibition (Sacubitril/Valsartan, i.e. ARNI) is recommended in heart failure guidelines for patients in NYHA class II-III with reduced left ventricular ejection fraction (LVEF). ARNI increase survival and quality of life; due to their hemodynamic effects, ARNI could also affect exercise tolerance. We studied the effects of ARNI on cardiopulmonary test (CPET) after six months of treatment in 35 patients [67 ± 11 years; LVEF 31 ± 6%; NT-proBNP 1822 ± 1651 pg/ml; ICD/CRT since at least 6 months in 26/35], treated with increasing doses of Sacubitril/Valsartan up to 318 ± 36 mg/die. In addition, levels of NT-proBNP, renal function, electrolytes, and echocardiocolorDoppler were assessed in the same time periods. No variations of renal function and/or potassium levels were observed; NT-proBNP decreased. Most CPET variables were improved by ARNI ( < .05): peak VO and O pulse increased (from 15.8 ± 3.4 to 17.0 ± 4.0 ml/kg/min and from 11.5 ± 2.5 to 12.6 ± 2.4 ml/beat, respectively), while VEVCO slope decreased from 35.2 ± 11.2 to 33.1 ± 12.3. A significant relationship ( < .05) was observed between the amount of increase in LVEF and that of O pulse in all patients, and between the amount of decrease in PAPs and that of VEVCO slope in patients showing pulmonary hypertension in baseline. In a subgroup of 22 patients who already completed A 1 year follow-up, overall CPET improvement was maintained. In conclusion, already in the short term ARNI favourably affect cardiopulmonary response to exercise in heart failure patients; such a change seems to be preserved on a longer period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00015385.2019.1669317 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).
Heart Fail Rev
January 2025
Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Heart failure (HF) represents a significant global health challenge, characterized by high morbidity and mortality rates, decreased quality of life and a significant financial and economic burden. The prevalence of HF continues to rise, driven by an ageing population and an increasing burden of comorbidities such as hypertension, diabetes and obesity. Understanding the complex pathophysiology and developing effective treatments are critical for improving patient outcomes, yet the range of effective, life-prolonging medication classes has remained mostly constant in the last few decades.
View Article and Find Full Text PDFA Systematic Review and Meta-Analysis of an Angiotensin Receptor-Neprilysin Inhibitor in Patients Using a Durable Left Ventricular Assist Device.
J Clin Med
December 2024
School of Medicine, College of Medicine Nursing and Health Sciences, University of Galway, H91 TK33 Galway, Ireland.
Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) drug used to treat patients with heart failure and has shown improvement in outcomes. Different studies reported the use of an ARNI in patients using left ventricular assist devices (LVADs). However, there are limited data on the use of ARNIs in this population.
View Article and Find Full Text PDFSacubitril/Valsartan and Dapagliflozin in Patients with a Failing Systemic Right Ventricle: Effects on the Arrhythmic Burden.
J Clin Med
December 2024
Adult Congenital Heart Disease and Congenital and Familial Arrhythmias Unit, Monaldi Hospital, Leonardo Bianchi Street, 80131 Naples, Italy.
: Angiotensin receptor neprilysin inhibitor (ARNI) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) are essential medications in heart failure (HF) therapy, and their potential antiarrhythmic effects have been reported. Recently, ARNI and SGLT2i use for HF in adult congenital heart disease (ACHD) has been studied. However, whether any beneficial effects may be achieved on the arrhythmic burden in the complex population of ACHD with a systemic right ventricle (sRV) is still to be determined.
View Article and Find Full Text PDFSex differences and clinical outcomes, including ventricular tachyarrhythmias, of patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
Front Cardiovasc Med
December 2024
Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, Medical Faculty Mannheim, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
Background: Women with heart failure with reduced ejection fraction (HFrEF) often experience worse clinical outcomes compared to men, including higher rates of mortality, hospitalization, and congestion. However, the effects of sacubitril/valsartan on these outcomes, as well as on ventricular tachyarrhythmias, have not been well studied in women with HFrEF.
Methods: This study included consecutive series of patients treated with sacubitril/valsartan at University Hospital Mannheim from 2016 to 2020.
Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction.
Cardiovasc Ther
January 2025
Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- Heart failure and renal dysfunction often occur together, creating complex interactions that negatively affect patient outcomes.
- The drug sacubitril/valsartan shows promise in improving heart and kidney health in heart failure patients with reduced ejection fraction, potentially slowing kidney function decline.
- However, more evidence is needed to confirm its safety in preventing hyperkalemia and worsening kidney function, emphasizing the need for personalized treatment strategies and further research into heart-kidney interactions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!